CALICHEAMICIN | CALICHEAMICIN INOTUZUMAB OZOGAMICIN GEMTUZUMAB OZOGAMICIN | ATC L01FB01
ANTINEOPLASTIC TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) CD33- OR CD22-DIRECTED ANTIBODY-DRUG CONJUGATE (ADC) RELEASE OF N-ACETYL-GAMMA-CALICHEAMICIN THAT CAUSES DOUBLE-STRANDED DNA BREAKS | INJECTION | PPB 97 PERCENT | DNA | B-cell receptor CD22 UNIPROT P20273 more at DrugCentral | EMA ANSM (in French) Inxight Drugs Dailymed Drugs.com SIDER side effects Chemical Probes Portal ChEMBL BindingDB DrugBank |